Human Breast Cell T-47D based Proliferation Assay Service
At Creative Biolabs, we specialize in providing high-fidelity in vitro solutions to accelerate cancer research. Our human breast cell T-47D based proliferation assay service offers a highly reliable, quantitative, and reproducible platform. This service is positioned as the industry gold standard for evaluating novel anti-cancer agents, particularly those targeting hormone-responsive pathways (like estrogen or progesterone receptors). This robust assay is crucial for rapidly and accurately determining the efficacy and IC50 of your therapeutic candidates, making informed decisions easier during early drug discovery.
Background What We Can Offer Workflow Why Choose Us FAQs Customer Review Related Services Contact Us
The T-47D Model: A Pillar of ER-Positive Oncology Research
The T-47D cell line, derived from an infiltrating ductal carcinoma, is an indispensable tool in endocrine research due to its inherent molecular characteristics. Its estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) status allows for the rigorous testing of selective ER modulators (SERMs), selective ER degraders (SERDs), and aromatase inhibitors, while facilitating the exploration of distinct PR roles. Retaining an epithelial morphology and exhibiting molecular consistency, these cells offer a predictable and robust system for investigating and modulating fundamental proliferation pathways, such as the PI3K/AKT/mTOR and PR-regulated MAPK pathways.
How Creative Biolabs' Proliferation Assay Can Assist Your Project
Precision IC50 Determination for Potency Ranking
We generate highly reproducible, multi-point dose-response curves to precisely calculate IC50 and IC90 values. This allows for the transparent ranking of novel candidates against gold-standard agents, providing data required for submissions.
Advanced Cross-Resistance and Synergy Profiling
We design intricate combination studies (e.g., with PI3K or CDK4/6 inhibitors) to accurately model clinical strategies. This predicts therapeutic synergy and preemptively assesses cross-resistance profiles, guiding optimal clinical trial design.
Deep Mechanistic Insights into PR-Regulated Pathways
Leveraging the cell line's ER/PR co-expression, we confirm whether your agent affects critical survival pathways. We can integrate p-ERK analysis to generate compelling evidence that your strategy effectively overrides growth factor-induced signaling, such as the P4/PR anti-proliferative axis.
Are you looking to test a combination regimen? Contact Creative Biolabs today to design a custom synergy matrix for your lead compound.
Workflow: Comprehensive Steps for Reliable Data
Our structured, phased workflow ensures transparency and quality at every stage, delivering robust results suitable for regulatory submissions and mechanistic publications.
Why Choose Us
Creative Biolabs sets the benchmark for in vitro oncology services by prioritizing data quality. We provide superior sensitivity with luciferase technology, offering a stable reporter system with a superior dynamic range over legacy MTT/SRB methods, resulting in more precise IC50 measurements by eliminating dye interference. We routinely calculate the essential therapeutic index by including parallel toxicity testing against normal breast cells (MCF10A), which reduces later attrition by down-selecting safer, more selective candidates. Furthermore, our expert mechanistic integration couples proliferation data with secondary molecular assays (western blot, RT-qPCR) to confirm the compound's biological mechanism (e.g., ERK1/2 phosphorylation), ensuring actionable intelligence.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q: Can you perform the assay under hormone-starved conditions?
A: Absolutely. We routinely perform the assay under various conditions, including complete hormone starvation (using charcoal-stripped serum) to evaluate SERDs in isolation, as well as in the presence of E2 or P4 to assess compounds that modulate hormone action.
Q: Is the T-47D assay suitable for testing non-endocrine drugs?
A: Yes, the T-47D model is an excellent and clinically relevant context for non-endocrine agents because it retains functional cell cycle regulation. We frequently use it to test CDK4/6 or PI3K pathway inhibitors, often combining them with endocrine agents to measure synergistic effects.
Q: What quality control measures ensure the reproducibility of the data?
A: Our rigorous QC includes pre-testing hormone receptor status, using validated reference compounds (IC50 controls), and strict SOPs, guaranteeing high data reproducibility across batches.
Customer Review
-
Accurate IC50 Values
Using Creative Biolabs' service in our research has significantly facilitated the comparative analysis of our SERD library. The consistency of the IC50 values allowed us to confidently distinguish between highly potent leads that were otherwise indistinguishable in our MTT screening. – Adrw*T
-
Selectivity and Safety Profile
Using Creative Biolabs' service in our research has significantly improved the calculation of our therapeutic window. The co-testing against MCF10A cells provided critical, high-quality data on cellular toxicity, allowing us to down-select safer candidates earlier in the process. – Mra*L
Related Services
To fully characterize your anti-cancer lead, Creative Biolabs offers several complementary services that are frequently utilized alongside the human breast cell T-47D based proliferation assay service:
Genotoxicity Assessment Services
Genotoxicity assessment evaluates a compound's potential to damage genetic material (DNA/chromosomes), providing critical safety data. Creative Biolabs offers a comprehensive range of regulatory and mechanistic assays.
Learn More →
Protease Assay Service
Creative Biolabs' protease assay service precisely measures secreted and intracellular proteases (e.g., granzymes, MMPs), pivotal in immune-oncology, supporting high-throughput screening for novel therapeutic modulators.
Learn More →
Contact Us
Creative Biolabs' human breast cell T-47D based proliferation assay service offers a robust, quantitative, and mechanistically relevant platform to accelerate your ER+ breast cancer drug development. By providing precise IC50 data and deep insights into hormone signaling, we ensure your therapeutic candidates are validated with the highest degree of confidence.
Connect with a Creative Biolabs specialist to design your custom T-47D proliferation assay and take the next decisive step in your oncology drug development journey.
